Fractyl Health Inc

Financials

Flusso di cassa derivante dalle attività operative -65.52 M-90.33 M -90.33 M Flussi di cassa derivanti dalle attività di investimento -1.76 M-557 K -557 K Liquidità derivante dalle attività di finanziamento 101.23 M104.96 M 104.96 M Liquidità libera -67.29 M-90.89 M -90.89 M

Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.

GUTS

Financials

Fractyl Health Inc

Notizie

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Fractyl Health: taglio costi nel Q4 2025, azioni in calo

Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fractyl Health: Low Market Expectations Create Trading Opportunity With 2026 Catalysts

Morgan Stanley declassa il titolo Fractyl Health a Equalweight dopo i risultati del trial Revita

Morgan Stanley downgrades Fractyl Health stock rating to Equalweight on Revita trial results

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11%

Why Is Fractyl Health Stock Tumbling Today? - Fractyl Health (NASDAQ:GUTS)

Il titolo di Fractyl Health crolla dopo i dati intermedi sul mantenimento del peso con GLP-1

Il trattamento Revita promette di mantenere il peso dopo l’uso di GLP-1

Fractyl Health stock falls after midpoint data on GLP-1 weight maintenance

Revita treatment shows promise for weight maintenance after GLP-1 use